Drug intelligence / Profile preview

HNG-P(DEGMA-co-IA12)

Development stage: Preclinical
Lead developer: Universidad Nacional de Córdoba
Modality: Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Intravenous

Overview

HNG-P(DEGMA-co-IA12) is an experimental hybrid nanogel (HNG) platform designed for stimuli-responsive drug delivery. It consists of a mesoporous silica nanoparticle (MSN) core covalently integrated with a copolymer shell of di(ethylene glycol) methyl ether methacrylate (DEGMA) and itaconic acid (IA). The "IA12" designation typically refers to the molar percentage of the acidic co-monomer itaconic acid incorporated into the polymer structure. This hybrid material combines the high loading capacity of mesoporous silica with the thermo- and pH-responsive properties of the organic polymer. The nanogel undergoes a volume phase transition in response to environmental changes, allowing for controlled release of encapsulated payloads. Preclinical research has demonstrated its biocompatibility in fibroblast (NIH 3T3) and prostate cancer (LNCaP) cell lines, as well as its efficacy in delivering chemotherapeutic agents like camptothecin to inhibit cancer cell growth.

Other names: hybrid nanogel based on mesoporous silica nanoparticles and poly(di(ethylene glycol) methyl ether methacrylate-co-itaconic acid)MSN-P(DEGMA-co-IA12) hybrid nanogel

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on HNG-P(DEGMA-co-IA12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HNG-P(DEGMA-co-IA12).

Explore the full profile